Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists - PubMed (original) (raw)

Review

Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists

André J Scheen. Diabetes Res Clin Pract. 2017 May.

Abstract

Dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent two distinct classes of incretin-based therapies used for the treatment of type 2 diabetes. Non-inferiority versus placebo was shown in large prospective cardiovascular outcome trials in patients with high cardiovascular risk: SAVOR-TIMI 53 (saxagliptin), EXAMINE (alogliptin), and TECOS (sitagliptin); ELIXA (lixisenatide), LEADER (liraglutide) and SUSTAIN 6 (semaglutide). The promises raised by meta-analyses of phase 2-3 trials with DPP-4is were non confirmed as no cardiovascular protection could be evidenced. However, LEADER showed a significant reduction in major cardiovascular events, myocardial infarction, cardiovascular and all-cause mortality in patients treated by liraglutide compared to placebo. These positive results contrasted with the non-inferiority results with lixisenatide in ELIXA. They were partially confirmed with semaglutide in SUSTAIN 6 despite the absence of reduction in cardiovascular mortality. Hospitalisation for heart failure was not increased except with saxagliptin in SAVOR-TIMI 53. The reasons for different outcomes between trials remain largely unknown as well as the precise underlying mechanisms explaining the cardiovascular protection by liraglutide. The clinical relevance of results with DPP-4is and GLP-1RAs is discussed. Ongoing trials with linagliptin and several once-weekly GLP-1RAs should provide new insights into remaining fundamental questions.

Keywords: Cardiovascular disease; Clinical trial; DPP-4 inhibitors; GLP-1 receptor agonists; Mortality; Type 2 diabetes.

PubMed Disclaimer

Cited by

Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease.
Hershon KS, Hirsch BR, Odugbesan O. Hershon KS, et al. Clin Diabetes. 2019 Jul;37(3):250-259. doi: 10.2337/cd18-0040. Clin Diabetes. 2019. PMID: 31371856 Free PMC article.
Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study.
Lin YH, Huang YY, Wu YL, Lin CW, Chen PC, Chang CJ, Hsieh SH, Sun JH, Chen ST, Lin CH. Lin YH, et al. Diabetol Metab Syndr. 2018 Oct 17;10:75. doi: 10.1186/s13098-018-0378-6. eCollection 2018. Diabetol Metab Syndr. 2018. PMID: 30349614 Free PMC article.
Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway.
Wu L, Wang K, Wang W, Wen Z, Wang P, Liu L, Wang DW. Wu L, et al. Aging Cell. 2018 Aug;17(4):e12763. doi: 10.1111/acel.12763. Epub 2018 Apr 16. Aging Cell. 2018. PMID: 29659121 Free PMC article.
Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.
Røder ME. Røder ME. Ther Adv Chronic Dis. 2018 Jan;9(1):33-50. doi: 10.1177/2040622317735283. Epub 2017 Nov 9. Ther Adv Chronic Dis. 2018. PMID: 29344329 Free PMC article. Review.
Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis.
Marfella R, Sardu C, Balestrieri ML, Siniscalchi M, Minicucci F, Signoriello G, Calabrò P, Mauro C, Pieretti G, Coppola A, Nicoletti G, Rizzo MR, Paolisso G, Barbieri M. Marfella R, et al. Diabetol Metab Syndr. 2018 Jan 3;10:1. doi: 10.1186/s13098-017-0304-3. eCollection 2018. Diabetol Metab Syndr. 2018. PMID: 29308090 Free PMC article.

Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists - PubMed (original) (raw)